In nuclear medicine, the term theranostics describes the combination of therapy and diagnostic imaging. In practice, this concept dates back more than 50 years; however, among the most successful examples of theranostics are peptide receptor scintigraphy and peptide receptor radionuclide therapy of neuroendocrine tumors. The development of these modalities through the radiolabeling of somatostatin analogs with various radionuclides has led to a revolution in patient management and established a foundation for expansion of the theranostic principle into other oncology indications. This article provides a review of the evolution and development of the theranostic radionuclide approach to the management of neuroendocrine tumors, as described by the inventor of this technique, Eric P. Krenning, in an interview with Rachel Levine.

Additional Metadata
Keywords Neuroendocrine, Peptide, PRRT, PSMA, Somatostatin
Persistent URL dx.doi.org/10.2967/jnumed.116.186502, hdl.handle.net/1765/101818
Journal The Journal of Nuclear Medicine
Citation
Levine, R. (Rachel), & Krenning, E.P. (2017). Clinical history of the theranostic radionuclide approach to neuroendocrine tumors and other types of cancer. The Journal of Nuclear Medicine (Vol. 58, pp. 3S–9S). doi:10.2967/jnumed.116.186502